Autolus

London, United Kingdom Founded: 2015 • Age: 11 yrs Listed
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.

About Autolus

Autolus is a publicly listed company based in London (United Kingdom) founded in 2015. Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. Autolus has raised $181.37 million across 5 funding rounds from investors including BioNTech, Blackstone and Syncona. The company has 647 employees. Its chief executive, as recorded, is Christian Martin Itin. Its website autolus.com draws about 22 thousand monthly visits. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is AUTOLUS LIMITED.

Company details

Autolus was founded in 2015 in London, United Kingdom, within the biotechnology sector. Engineered T-cell therapies are developed and commercialized by the company, targeting hematological and solid tumors. A pipeline of CAR T-cell products is advanced using proprietary targets, constructs, and technologies. Emphasis is placed on immunotherapy applications for cancer and auto-immune conditions.

  • Headquarters London, United Kingdom
  • Employees 647
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website autolus.com
  • Social LinkedIn
  • Legal Name Autolus Therapeutics Plc Sponsored Adr
Key Metrics
  • Annual Revenue
    $75.56 M (USD)
    646.37
    as on Dec 31, 2025
  • Net Profit
    -$288.2 M (USD)
    -30.55
    as on Dec 31, 2025
  • EBITDA
    -$271.6 M (USD)
    -27.24
    as on Dec 31, 2025
  • Total Equity Funding
    $181.37M (USD)

    in 5 rounds

  • Latest Funding Round
    $200M (USD), Post-IPO

    Feb 2024

  • Investors
    BioNTech

    & 5 more

  • Employee Count
    647

Funding Insights of Autolus

Autolus has successfully raised a total of $181.37M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $181.37M
  • Total Rounds 5
  • Last Round Post-IPO β€” $200M
  • First Round $45.4M

    (Jan 2015)

  • Investors Count 6

All 5 funding rounds of Autolus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2024$200MPost-IPO––
Nov 2021Post-IPO––
Sep 2017$80MSeries C–Syncona
Mar 2016$55.97MSeries B––
Jan 2015$45.4MSeries A––
Valuation history

6 investors in total: 6 institutional.

Investors in Autolus

Autolus has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include BioNTech, Blackstone and Syncona.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Diversified investment management is provided across multiple asset classes.
1985blackstone.comNew York, United States
PE firm investing in the US
nextechinvest.comZurich, Switzerland
Healthcare investments are managed via private equity by Syncona.
2012synconaltd.comLondon, United Kingdom
Investments in biotech startups are made by Arix Bioscience.
2016arixbioscience.comLondon, United Kingdom
Immunotherapeutics for cancer and other diseases are developed.
2008biontech.comMainz, Germany
Diversified investment portfolios are managed for clients by the firm.
2014woodfordfunds.comSwindon, United Kingdom
Premium access

Investor details for Autolus

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Autolus

137 people are tracked at Autolus (62 in leadership, 75 in team); the tracked headcount is 647.

NameRoleGroup
Linda Catharina Bain
Non-Executive DirectorLeadership
Cynthia Marie Butitta
Independent Non-Executive DirectorLeadership
John Berriman
Non-Executive DirectorLeadership
Christian Martin Itin
CEOLeadership
Martin Pule
SVP, Founder & Chief Scientific OfficerLeadership
Christopher Vann
SVP & Chief Operating OfficerLeadership
Matthew N.
Associate Director Of Apheresis & Infusion OperationsLeadership
Adam Cooper
Associate Director Of ProductionLeadership
Christian Lang
Senior Director, Strategic Center EngagementLeadership
Lindsay Luke
Vp, Centre Engagement & Alliance ManagementLeadership
Alexander Swan
Chief Human Resources OfficerLeadership
Leila Mekkaoui
DirectorLeadership
Christopher Fisher
Director Material Sciences, Manufacturing Strategy And TechnologyLeadership
Marcos Giovannoni
Director, ProductionLeadership
Christian Itin
Chairman & CEOLeadership
Melia Loskill
Vice President Of Market AccessLeadership
Austin Fisher
Vice President, Patient & Channel AccessLeadership
Charles Skinner Bsc Aca
Senior Director, Group Financial ControllerLeadership
Andrew Bolton
Associate Director, ProductionLeadership
Gerardo Santiago Toledo
Associate Director, Cell Process DevelopmentLeadership

117 more people are available in the full profile.

Premium access

Complete people profiles for Autolus

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Autolus

Autolus is a publicly listed company on the NASDAQ with ticker symbol AUTL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date27 Jul 2018
  • Listed onFRA: 6A3A
  • Listed entityAutolus Therapeutics Plc Sponsored ADR
  • Exchange sectorHealth technology
  • ISINUS05280R1005
  • Share price$1.62 (-6.9% on the day) · 2026-10-13
  • Market capitalisation$431.2M
  • EPS (diluted, trailing year)$-1.05
  • Volume (last session)2,420,302

Financials of Autolus

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$75.6M-$288.2M-$271.6M
2024$10.1M-$220.8M-$213.5M
2023$1.7M-$209.2M-$189.2M
2022$6.2M-$148.8M-$160.1M
2021$1.5M-$142.1M-$156.6M
Premium access

Detailed financial statements for Autolus

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Autolus

4 dated milestones of Autolus across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Autolus is founded.
  2. Funding First funding round of $45.4M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $200.0M.

Web traffic of Autolus

The website of Autolus (autolus.com) receives about 22K visits a month and ranks #1,467,054 among all websites worldwide, #1,917 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    22K

    ▲ 10.4% vs previous month

  • Unique visitors
    6.6K

    per month

  • Global rank
    #1,467,054

    among all websites

  • Category rank
    #1,917

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Autolus. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
bioinformant.com
bioinformant.com
100%
#761,820–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Autolus

Premium access

Complete news archive for Autolus

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Autolus

Autolus was founded in 2015.

Autolus is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Christian Martin Itin is the CEO of Autolus, as recorded in our data.

Autolus is a funded company, having raised a total of $181.37M across 5 funding rounds to date. The company's 1st funding round was a Series A of $45.4M, raised on Jan 2015.

Autolus has 647 employees.

Annual revenue of Autolus is $75.56M as on Dec 31, 2025.

Autolus was founded in 2015 in London, United Kingdom, within the biotechnology sector. Engineered T-cell therapies are developed and commercialized by the company, targeting hematological and solid tumors. A pipeline of CAR T-cell products is advanced using proprietary targets, constructs, and technologies. Emphasis is placed on immunotherapy applications for cancer and auto-immune conditions.

Yes, Autolus is publicly traded on NASDAQ under the ticker symbol AUTL.

Autolus has 6 investors. Key investors include BioNTech, Blackstone, Syncona, Arix Bioscience, and Woodford Investment Management.

Autolus operates through Autolus Limited.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available